STAAR Surgical Reports Third Quarter 2024 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024. Third Quarter 2024 Overview Net sales of $88.6 million, up 10% from prior year quarter ICL sales of $89.1 million, up 10% from prior year quarter Gross margin of 77.3% as compared to 79.2% year